Fundación Fls De Lucha Contra El Sida, Las Enfermedades Infecciosas Y La Promoción De La Salud Y La Ciencia
Clinical trials sponsored by Fundación Fls De Lucha Contra El Sida, Las Enfermedades Infecciosas Y La Promoción De La Salud Y La Ciencia, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a cancer drug ease long COVID? new trial aims to find out Results expected Sep 2026 (estimated)
- Brain training app takes on long COVID disability Results expected Nov 2026 (estimated)
- Can a 10-day antiviral course protect kidney transplant patients from severe COVID? Results expected Dec 2026 (estimated)
-
Could moving HIV care out of hospitals boost satisfaction and cut carbon?
Disease control CompletedThis pilot study tests whether people with HIV who receive routine care at a community center, instead of a hospital, feel more satisfied with their care. Researchers will compare satisfaction between two groups: one getting care at the community facility and one continuing usual…
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a pill replace the syphilis shot? new trial tests oral antibiotic
Disease control CompletedThis trial compares an oral antibiotic called linezolid to the standard penicillin injection for treating early syphilis. Linezolid can reach the brain, which may help prevent neurosyphilis. About 224 adults with primary, secondary, or early latent syphilis will be randomly assig…
Phase 3 • Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common antibiotic beat yaws? new trial puts linezolid to the test
Disease control CompletedThis phase 3 trial investigates whether the antibiotic linezolid can cure yaws, a bacterial skin infection that causes ulcers, as effectively as the standard treatment azithromycin. The study involves 384 children aged 5 to 18 with confirmed yaws. Participants receive either line…
Phase 3 • Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can an arthritis drug help control HIV? new study investigates
Disease control CompletedThis study tests whether baricitinib, a drug used for arthritis, can safely reduce the hidden HIV reservoirs in people who already have the virus under control with standard HIV medication. Thirty adults with HIV will take either baricitinib or a placebo daily for 12 weeks while …
Phase 2 • Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Phone app aims to clear COVID brain fog
Symptom relief CompletedThis study tested a 12-week smartphone program called SuperCAP for people with post-COVID syndrome. The program includes daily games, exercises, and videos to improve thinking, mood, and daily function. Sixty adults with ongoing cognitive complaints took part, and researchers mea…
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Mpox secrets revealed: new study tracks virus clearance and transmission
Knowledge-focused CompletedThis completed study looked at 550 people with mpox to see how long the virus stays in the body and how it spreads to close contacts. Researchers measured viral levels in skin lesions, throat swabs, and blood over time. The goal is to provide better guidance on when it's safe to …
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC